ライフサイエンスコーパス: adenosine A(1) receptor

1 irments could be ameliorated by blocking the adenosine A1 receptor.

2 tion than that produced by activation of the adenosine A1 receptor.

3 opamine D2, metabotropic glutamate mGlu5 and adenosine A1 receptors.

4 a subunits rescued presynaptic inhibition by adenosine A1 receptors.

5 ction by ethanol is mediated through myocyte adenosine A1 receptors.

6 ry effect appears to be due to activation of adenosine A1 receptors.

7 europrotection through activation of central adenosine A1 receptors.

8 more heterogeneous activation of presynaptic adenosine A1 receptors.

9 could transiently be provoked after blocking adenosine A1 receptors.

10 vity for adenosine A(2a) receptor versus the adenosine A(1) receptor.

11 h displayed an affinity of 7 nM on the human adenosine A(1) receptor.

12 is response is mediated by the activation of adenosine A(1) receptors.

13 neurons in vitro by activating postsynaptic adenosine A(1) receptors.

14 r/middle lateral RA had significantly higher adenosine A1 receptor (2.7+/-1.7-fold; P<0.01) and GIRK4

15 tency (hA1, Ki=7 nM) and selectivity for the adenosine A1 receptor (915-fold versus adenosine A2A rec

16 Adenosine A(1) receptor (A(1)AR) agonists have antinocic

17 The adenosine A(1) receptor (A(1)AR) is a G-protein-coupled

18 including cannabinoid receptor 2 (CB2R) and adenosine A(1) receptor (A(1)AR), protects against noise

19 Transient adenosine A(1) receptor (A(1)R) activation in rabbits in

20 t infarction in rabbits 24 to 72 hours after adenosine A(1) receptor (A(1)R) activation.

21 chemoreactive and clickable) ligands for the adenosine A(1) receptor (A(1)R) and adenosine A(3) recep

22 nic pain through sustained activation of the adenosine A(1) receptor (A(1)R) and phospholipase C-medi

23 Activation of adenosine A(1) receptor (A(1)R) by N(6)-cyclopentidylade

24 positive allosteric modulators (PAMs) of the adenosine A(1) receptor (A(1)R) in Gi protein dissociati

25 steric modulators of agonist function at the adenosine A(1) receptor (A(1)R) in two different functio

26 The adenosine A(1) receptor (A(1)R) is a promising therapeut

27 nding pockets and apply this approach to the adenosine A(1) receptor (A(1)R).

28 monophosphonate, ACP) directly activated the adenosine A(1) receptor (A(1)R).

29 50% in Nt5e(-/-) mice and were eliminated in Adenosine A(1) receptor (A(1)R, Adora1) knock-out mice.

30 Adenosine A(1) receptors (A(1)AR) are well characterized

31 yed preconditioning induced by activation of adenosine A(1) receptors (A(1)ARs) is not fully understo

32 attenuated by activation of either H(3)R or adenosine A(1) receptors (A(1)R).

33 This is especially the case for adenosine A(1) receptors (A(1)Rs) whose clinical potenti

34 Adenosine A1 receptor (A1-AdoR) function in rat ventricl

35 ic and diuretic action of a highly selective adenosine A1 receptor (A1AdoR) antagonist, 1,3-dipropyl-

36 the hypothesis that a partial agonist of the adenosine A1 receptor (A1AdoR) may cause a greater atten

37 In this study, we targeted the cochlear adenosine A1 receptor (A1AR) by trans-tympanic injection

38 In this study, we show that the adenosine A1 receptor (A1AR) protects against cisplatin

39 Adenosine A1 receptor (A1AR) subtype present on renal pr

40 Allosteric modulation of adenosine A1 receptors (A1ARs) offers a novel therapeuti

41 Neurabin attenuated adenosine A(1) receptor (A1R) signaling by assembling a

42 duced long-term depression (LTD) mediated by adenosine A1 receptor (A1R) activation at corticostriata

43 Adenosine A1 receptor (A1R) agonist N6-cyclopentyl-adeno

44 CPA, a stable adenosine A1 receptor (A1R) agonist, did not affect KDR

45 l blockade of A1 receptor signaling using an adenosine A1 receptor (A1R) antagonist, 8-cyclopentyl-1,

46 ne induces cortical actin polymerization via adenosine A1 receptor (A1R) induction of a Rho GTPase CD

47 The adenosine A1 receptor (A1R) is a key mediator of the neu

48 neuronal activity through activation of the adenosine A1 receptor (A1R), resulting in antinociceptio

49 els around synapses resulting in an enhanced adenosine A1 receptor (A1R)-dependent protective tone de

50 adenosine alleviates pain by activating the adenosine A1 receptor (A1R).

51 rogeneous expression of If, INa currents and adenosine A1 receptors (A1R) across SAN pacemaker-conduc

52 on upregulate adenosine concentration and/or adenosine A1 receptors (A1R) in the brain.

53 Adenosine A(1) receptors (A1Rs) are prolific within stri

54 This action is shared by adenosine A(1) receptors (A1Rs), which are also located

55 Activation of presynaptic adenosine A1 receptors (A1Rs) causes substantial synapti

56 Adenosine A1 receptors (A1Rs) in human and rodent brains

57 Because very little is known about adenosine A1 receptors (A1Rs) in the spinal cord, we det

58 In hippocampal neurons, activation of adenosine A1 receptors (A1Rs) or GABA(B) receptors on sy

59 plasticity by experimental manipulations to adenosine A1 receptors (A1Rs).

60 seizures in mice by increasing activation of adenosine A1 receptors (A1Rs).

61 ce of heterosynaptic plasticity; blockade of adenosine A1 receptors abolished it.

62 ce of heterosynaptic plasticity: blockade of adenosine A1 receptors abolished weight dependence, whil

63 ective when synaptic activity was reduced by adenosine A(1) receptor activation, and a combination of

64 Adenosine A1 receptor activation also impaired the expre

65 algesic effect of acupuncture is mediated by adenosine A1 receptor activation at the acupuncture poin

66 The inhibitory modulation of adenosine A1 receptor activation by hydroxylamine sugges

67 Adenosine A1 receptor activation depresses excitatory tr

68 Adenosine A1 receptor activation dose-dependently and se

69 P inhibited excitatory neurotransmission via adenosine A1 receptor activation in spinal cord slices f

70 this model of trigeminovascular nociception, adenosine A1 receptor activation leads to neuronal inhib

71 een reported in response to agonist-mediated adenosine A1 receptor activation, the implications of A2

72 -induced mechanical allodynia via peripheral adenosine A1 receptor activation.

73 is study, we report a novel dual role of the adenosine A1 receptor (Adora1) as an E2/ERalpha target a

74 ssion of a potential glucagon inhibitor, the adenosine A1 receptor (Adora1), is gradually diminished

75 sponses are thought to require activation of adenosine A1 receptors (adorA1Rs) and release of transmi

76 However, incubation with the adenosine A(1) receptor agonist 2-chlorocyclopentyladeno

77 ecular meshwork cells to the addition of the adenosine A(1) receptor agonist N(6)-cyclohexyladenosine

78 The adenosine A(1) receptor agonist N(6)-cyclohexyladenosine

79 to adenosine, N(6)-cyclopentyladenosine (an adenosine A(1) receptor agonist), and 2-[p-(2-carboxyeth

80 extent as ischemic preconditioning, but the adenosine A(1) receptor agonist, 2-chloro-N(6)-cyclopent

81 -D-aspartate receptor antagonist MK-801; the adenosine A1 receptor agonist 2-chloro-N6-cyclopentylade

82 the GABA(B) receptor agonist baclofen or the adenosine A1 receptor agonist 2-chloroadenosine, short-t

83 These data are consistent with adenosine A1 receptor agonist actions on REM sleep media

84 the NO donor sodium nitroprusside (SNP), the adenosine A1 receptor agonist CCPA (2-chloro-N6-cyclopen

85 osine A2a receptor agonist APEC, but not the adenosine A1 receptor agonist CHA, attenuated c-Fos indu

86 r-bearing mice was lowered to 32 C using the adenosine A1 receptor agonist N(6)-cyclohexyladenoxine t

87 Intrastriatal microinfusion of adenosine A1 receptor agonist N6-cyclohexyladenosine (CH

88 Pretreatment with the adenosine A1 receptor agonist N6-cyclohexyladenosine (CH

89 of the BF cholinergic neurons, the selective adenosine A1 receptor agonist N6-cyclohexyladenosine, ad

90 ditioning was mimicked by perfusion with the adenosine A1 receptor agonist N6-cyclopentyladenosine an

91 Microinjection of adenosine A1 receptor agonist or an inhibitor of adenyly

92 Direct injection of an adenosine A1 receptor agonist replicated the analgesic e

93 lisopropyl)-adenosine (R-PIA [50 nmol/L], an adenosine A1 receptor agonist), or 4 beta-phorbol 12-myr

94 The selective low efficacy adenosine A1 receptor agonist, GR190178 (30-1000 microg/

95 enous administration of the highly selective adenosine A1 receptor agonist, GR79236 (3-100 microg/kg)

96 adenoson bialanate, a first-in-class partial adenosine A1 receptor agonist, has the potential to impr

97 N6-Cyclopentyl adenosine (adenosine A1 receptor agonist, Kd = 1 nmol/l) did not af

98 Systemic injection of the selective adenosine A1 receptor agonist, N(6)-cyclohexyladenosine

99 lure was studied with the use of a selective adenosine A1 receptor agonist, N6-cyclohexyl-2'-O-methyl

100 In Experiment 1, the selective adenosine A1 receptor agonist, N6-cyclopentyladenosine (

101 A, 48.4+/-5.5% with SfA; P<0.001), CCPA (the adenosine A1-receptor agonist, 200 nmol/L) (24.9+/-4.5%

102 the effects of capadenoson (CAP), a partial adenosine A1-receptor agonist, on left ventricular (LV)

103 The selective adenosine A1 receptor agonists 2-chloro-N6-cyclopentylad

104 flammatory sites was signficantly reduced by adenosine A1 receptor agonists injected through intrathe

105 is a considerable literature to suggest that adenosine A1 receptor agonists may have anti-nociceptive

106 onists, nitric oxide synthase inhibitors and adenosine A1 receptor agonists.

107 The results support development of partial adenosine A1-receptor agonists for the treatment of chro

108 Therapy with adenosine A1-receptor agonists, however, is limited by u

109 Overexpressing the adenosine A1 receptor also led to increased protection a

110 Allosteric enhancers of the adenosine A1 receptor amplify signaling by orthosteric a

111 To confirm the involvement of adenosine A(1) receptors and matrix metalloproteinases (

112 amine D2 receptor, dopamine transporter, and adenosine A1 receptor and decreased adenosine A2A recept

113 al inhibition was blocked in the presence of adenosine A1 receptor and GABAB receptor blockade.

114 entry in RA areas with highest expression of adenosine A1 receptor and its downstream GIRK (G protein

115 denosine (2CA) and baclofen, agonists of the adenosine A1 receptor and the GABAB receptor, respective

116 previously produced up-regulation of central adenosine A1 receptors and created a state of opiate dep

117 e examined the manner in which activation of adenosine A1 receptors and GABAB receptors modulates syn

118 Given the similar involvement of NMDARs, adenosine A(1) receptors, and PP1 in depotentiation of L

119 ynthesis, which was prevented by blockade of adenosine A1 receptors, and decreased expression of gene

120 f ATP-sensitive potassium (K(ATP)) channels, adenosine A1 receptors, and the effects of different lev

121 attenuated by adrenergic alpha 2-receptors, adenosine A1-receptors, and histamine H3-receptors.

122 Moreover, adenosine A1 receptor antagonism had larger effects on t

123 s to cardiac arrhythmias and seizures due to adenosine A1-receptor antagonism.

124 enhanced pLTF (85 +/- 11%, P < 0.05), but an adenosine A(1) receptor antagonist (DPCPX, 3 microg kg(-

125 uced secretion of MMP-2 was inhibited by the adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dim

126 responses were not altered by the selective adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dip

127 ontrol hypoxic response, is inhibited by the adenosine A(1) receptor antagonist 8-cyclopentyl-1,3-dip

128 The adenosine A(1) receptor antagonist 8-cyclopentyltheophyl

129 Pretreatment with the adenosine A(1) receptor antagonist CPT (10 microM) or th

130 were also quantified after microinjecting an adenosine A(1) receptor antagonist into the prefrontal c

131 cerebrospinal fluid (aCSF) and two doses of adenosine A(1) receptor antagonist, 1,3-dipropyl-8-pheny

132 e evaluated in preparations treated with the adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-di

133 membrane, an effect that was blocked by the adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-di

134 BTI), or exogenous adenosine, or a selective adenosine A1 receptor antagonist (8-cyclopentyl-1, 3-dim

135 The adenosine A1 receptor antagonist 1,3-dipopylcyclopentylx

136 (19.6 +/- 0.9%) by systemic injection of the adenosine A1 receptor antagonist 8-CPT (2.5 mg kg(-1)) a

137 was largely reversed in the presence of the adenosine A1 receptor antagonist 8-cyclopentyl-1, 3-dipr

138 Both the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

139 (NOS) inhibitor l-NAME (Group 1, n = 8) and adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

140 The adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

141 denosine as a mediator of IPC, the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

142 The selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipro

143 roduced by the administration of a selective adenosine A1 receptor antagonist but not by a selective

144 Prior administration of the selective adenosine A1 receptor antagonist dipropylcyclopentylxant

145 GR79236 could be inhibited by the selective adenosine A1 receptor antagonist DPCPX (300 microg/kg; P

146 fore and after administration of a selective adenosine A1 receptor antagonist DPCPX (8-cyclopentyl-1,

147 value of 0.4 nM for antagonism of CPA by the adenosine A1 receptor antagonist DPCPX (8-cyclopentyl-1,

148 The adenosine A1 receptor antagonist DPCPX did not affect th

149 Intracerebroventricular infusion of an adenosine A1 receptor antagonist produced a similar decr

150 Here, we show that the adenosine A1 receptor antagonist rolofylline (KW-3902) i

151 Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patient

152 is comparable to that of BG9928, a selective adenosine A1 receptor antagonist that is currently in cl

153 yl-1,3-dipropylxanthine (DPCPX), a selective adenosine A1 receptor antagonist that is permeable to th

154 Imidazoline 14 is a competitive adenosine A1 receptor antagonist with a pA2 value of 8.8

155 -i]purin-5(4H)-one, is a particularly potent adenosine A1 receptor antagonist with good selectivity o

156 In the search for a selective adenosine A1 receptor antagonist with greater aqueous so

157 e presence of SPWs in slices treated with an adenosine A1 receptor antagonist, a finding that links t

158 ices treated with either a glial toxin or an adenosine A1 receptor antagonist.

159 blocked by protein kinase A inhibitor and an adenosine A1 receptor antagonist.

160 s with ADHF and volume overload, KW-3902, an adenosine A1-receptor antagonist, enhances the response

161 e hypothesis that the use of rolofylline, an adenosine A1-receptor antagonist, would improve dyspnea,

162 Adenosine A(1) receptor antagonists have been used effec

163 fibrillation were abolished or prevented by adenosine A1 receptor antagonists (50 mumol/L theophylli

164 The inhibition was blocked by adenosine A1 receptor antagonists and by agents that dis

165 Activation of the adenosine A(1)-receptor antagonizes responses elicited b

166 ns of the direct pathway, dopamine D(1)- and adenosine A(1)-receptors are coexpressed and are mutuall

167 vel tricyclic imidazoline antagonists of the adenosine A1 receptor are described.

168 cardial ischemia-reperfusion injury and that adenosine A1 receptors are required for this protective

169 These results indicate that adenosine A1 receptors are selectively upregulated durin

170 tion and increased neuronal excitability via adenosine A(1) receptors, ATP receptors, and ecto-ATPase

171 By contrast, adenosine A(1) receptor blockade did not prevent protect

172 ing new treatments, we studied the effect of adenosine A(1) receptor blockade or deletion on bone den

173 Adenosine A1 receptor blockade abolished the protection

174 67156) inhibition of nucleotide breakdown or adenosine A1 receptor blockade and reduced by apyrase in

175 Adenosine A1 receptor blockade with 4.5 mg/kg DPCPX admi

176 ht to evaluate the dose-dependent effects of adenosine A1-receptor blockade on diuresis and renal fun

177 yclopentyl-1, 3-dipropylxanthine (DPCPX) (an adenosine A1 receptor blocker).

178 manipulated by microperfusing nephrons with adenosine A1 receptor blocker, A1-agonist, or 5'-nucleot

179 gated by TRPV4 channel, GABAB, as well as an adenosine A1 receptor blocker.

180 rent and GIRK channel activation mediated by adenosine A(1) receptors, but not GABA(B) receptors.

181 iated by increased activation of presynaptic adenosine A1 receptors by endogenous adenosine.

182 Adenosine A1 receptor control of the homeostatic regulat

183 antisense oligodeoxynucleotide targeting the adenosine A1 receptor desensitized the animals to subseq

184 haracterize SAN structure, SAN function, and adenosine A1 receptor expression in control (n=17) and 4

185 ption of caffeine during adulthood increased adenosine A1 receptor expression in the NAc, but no othe

186 d that its anti-nociceptive actions required adenosine A1 receptor expression.

187 were conducted to examine the importance of adenosine A1 receptors for the acquisition and expressio

188 chemia might be attributable to the enhanced adenosine A1 receptor function on synaptic transmission,

189 ibitory G-protein-coupled receptors (GPCRs) (adenosine A(1) receptors, GABA(B) receptors, metabotropi

190 lized in lateral RA regions with the highest adenosine A1 receptor/GIRK4 expression.

191 To inhibit K(ATP) channels or adenosine A1 receptors, glibenclamide (0.1 mg/kg icv; n

192 5-cyano-2-thiopyrimidines as selective human adenosine A1 receptor (hA1AR) agonists with tunable bind

193 prior work demonstrated that the blockade of adenosine A1 receptors impairs heterosynaptic plasticity

194 tively attenuates discordantly overexpressed adenosine A(1) receptors in allergic lung.

195 ide evidence for the existence of functional adenosine A(1) receptors in the trabecular cells and tha

196 ffects, and we sought to explore the role of adenosine A1 receptors in a model of trigeminovascular n

197 Stimulation of renal adenosine A1 receptors in animal models has resulted in

198 blood brain barrier, we examine the role of adenosine A1 receptors in mediating cortical blood flow

199 d by endogenous GABAB, serotonin 5-HT1A, and adenosine A1 receptors in neurons coinfected with GIRK1+

200 In vitro studies supported roles for adenosine A1 receptors in promoting fatty acid synthesis

201 ncreases the concentrations of adenosine and adenosine A1 receptors in specific regions of the brain.

202 tissue thermogenesis, and that activation of adenosine A1 receptors in the CNS can block the brown ad

203 al (AAV) vector to focally delete endogenous adenosine A1 receptors in the hippocampus.

204 alothane level but not of K(ATP) channels or adenosine A1 receptors in the preconditioning effects of

205 entylxanthine, indicating the involvement of adenosine A1 receptors in the protection.

206 gical evidence supporting the involvement of adenosine A1 receptors in the regulation of the response

207 response (HVR), and investigated the role of adenosine A1 receptors in these SF effects in conscious

208 This effect requires functional adenosine A1 receptors, in line with the observation tha

209 ition, the role of adenosine--acting through adenosine A(1) receptors--in renal autoregulation has be

210 ptor antagonists and completely abolished by adenosine A(1) receptor inhibition.

211 (l-NAME, 1.5 mM), but was not affected by an adenosine A1 receptor inhibitor, 8-cyclopentyl-1,3-dipro

212 The adenosine A(1) receptor is a therapeutic target based on

213 While activation of inhibitory adenosine A(1) receptors is beneficial in epilepsy, chro

214 e first time in the mammalian fetus that the adenosine A1 receptor is an important mediator of brain

215 uction or oxygen consumption, suggesting the adenosine A1 receptor is involved in lowering metabolic

216 We show that, in adenosine A1 receptor knock-out mice, impaired synaptic

217 t-limiting protection of PostC was absent in adenosine A(1) receptor knockout mice (34.9+/-2.7%) or b

218 The bone mineral density (BMD) in adenosine A(1) receptor-knockout (A(1)R-knockout) mice w

219 Studies have shown that the activation of adenosine A(1) receptors lower intraocular pressure prim

220 Furthermore, activation of adenosine A1-receptors markedly attenuated norepinephrin

221 These results suggest that the adenosine A(1) receptor may be a useful target in treati

222 xperiments, hydroxylamine did not affect the adenosine A(1) receptor-mediated depression of postsynap

223 ydroxylamine acts presynaptically to counter adenosine A(1) receptor-mediated inhibition of synaptic

224 veal a novel role for the PP2A holoenzyme in adenosine A(1) receptor-mediated regulation of NHE1 acti

225 l natriuretic peptide level, consistent with adenosine A1 receptor-mediated activity, was observed.

226 A3 receptors with Cl-IB-MECA antagonized the adenosine A1 receptor-mediated inhibition of excitatory

227 These data provide good evidence for an adenosine A1 receptor-mediated inhibition of mAChR-media

228 GABA does not appear to be involved in adenosine A1 receptor-mediated inhibition of neuronal fi

229 In addition, hydroxylamine reversed adenosine A1 receptor-mediated inhibition of the evoked

230 Agents that inhibit adenosine A1 receptors might be useful in the treatment

231 Adenosine A1 receptors modulate baseline synaptic transm

232 or agonists directly reduces tremor, whereas adenosine A1 receptor-null mice show involuntary movemen

233 A presynaptic site of action for adenosine A(1) receptors on glutamatergic afferents was

234 nd Western analysis revealed the presence of adenosine A(1) receptors on trigeminal neurons.

235 Activation of either adenosine A1 receptors or GABAB receptors inhibits many

236 sine induces adipogenesis through peripheral adenosine A(1) receptor (pADORA(1)) signaling; however,

237 olar constriction, a process mediated by the adenosine/A1 receptor pathway.

238 lly, we show that blocking the activation of adenosine A1 receptors prevents the long-term depression

239 This study revealed a 3-fold RA-to-LA adenosine A1 receptor protein expression gradient in the

240 Adenosine A1 receptor protein expression was significant

241 had no effect, but those for adrenergic and adenosine A1 receptors reduced firing.

242 er, our data indicate that activation of the adenosine A1 receptor reduces synaptic strength by modul

243 Upon solubilization, the retinal adenosine A1 receptor retained binding characteristics s

244 yl-1,3-dipropylxanthine (DPCPX) (100 ng), an adenosine A(1) receptor selective antagonist, completely

245 be potently and effectively inhibited by the adenosine A(1) receptor-selective agonist GR79236X (pIC(

246 -induced motor incoordination in mice by the adenosine A(1) receptor-selective agonist N(6)-cyclohexy

247 at caffeine, because of its ability to block adenosine A1 receptors, shares neurochemical properties

248 mals received intravitreal injections of the adenosine A1 receptor stimulant adenosine amine congener

249 Adenosine A(1) receptor stimulation inhibits this respon

250 osine mediates neuroprotection by activating adenosine A(1) receptor subtype (A(1)AR) linked to suppr

251 The selectivity level over the adenosine A1 receptor subtype for some of the more activ

252 to be mediated by a pathway initiated at the adenosine A1 receptor that transduced signals through a

253 uction in IOP results from the activation of adenosine A1 receptors, the mechanisms responsible for t

254 sites flanking the major coding exon for the adenosine A1 receptor, this AAV-Cre markedly reduced A1

255 In chronic HF, adenosine A1 receptor upregulation in SAN pacemaker and

256 tivation of a postsynaptic K+ conductance by adenosine A1 receptors was used to determine the rate of

257 t cardiac ventricular myocytes, 67 +/- 5% of adenosine A(1) receptors were isolated with caveolae.

258 for GABA(B) receptors, 5HT1A receptors, and adenosine A1 receptors were essentially absent in mutant

259 In addition, we found that adenosine A1 receptors were required for astrocyte calci

260 As an example we show that the adenosine A1 receptor, when placed under the influence o

261 Activation of the adenosine A1 receptor with CCPA or the A3 receptor with

262 The results provide novel evidence that adenosine A(1) receptors within the prefrontal cortex co

263 In this study, we tested the hypothesis that adenosine A(1) receptors would translocate to caveolae i